Hauser RA - Search Results

1

Levodopa/carbidopa/entacapone in Parkinson's disease.

Seeberger LC, Hauser RA. Seeberger LC, et al. Among authors: hauser ra. Expert Rev Neurother. 2009 Jul;9(7):929-40. doi: 10.1586/ern.09.64. Expert Rev Neurother. 2009. PMID: 19589043

2

Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study.

Truong D, Duane DD, Jankovic J, Singer C, Seeberger LC, Comella CL, Lew MF, Rodnitzky RL, Danisi FO, Sutton JP, Charles PD, Hauser RA, Sheean GL. Truong D, et al. Among authors: hauser ra. Mov Disord. 2005 Jul;20(7):783-91. doi: 10.1002/mds.20403. Mov Disord. 2005. PMID: 15736159 Clinical Trial.

3

Ropinirole therapy for Parkinson's disease.

Pahwa R, Lyons KE, Hauser RA. Pahwa R, et al. Among authors: hauser ra. Expert Rev Neurother. 2004 Jul;4(4):581-8. doi: 10.1586/14737175.4.4.581. Expert Rev Neurother. 2004. PMID: 15853577 Review.

4

Open-label pilot study of levetiracetam (Keppra) for the treatment of levodopa-induced dyskinesias in Parkinson's disease.

Zesiewicz TA, Sullivan KL, Maldonado JL, Tatum WO, Hauser RA. Zesiewicz TA, et al. Among authors: hauser ra. Mov Disord. 2005 Sep;20(9):1205-9. doi: 10.1002/mds.20563. Mov Disord. 2005. PMID: 15954135

5

The controversy concerning plasma homocysteine in Parkinson disease patients treated with levodopa alone or with entacapone: effects of vitamin status.

Zesiewicz TA, Wecker L, Sullivan KL, Merlin LR, Hauser RA. Zesiewicz TA, et al. Among authors: hauser ra. Clin Neuropharmacol. 2006 May-Jun;29(3):106-11. doi: 10.1097/01.WNF.0000220817.94102.95. Clin Neuropharmacol. 2006. PMID: 16772808 Review.

6

Long-term care of Parkinson's disease. Strategies for managing "wearing off" symptom re-emergence and dyskinesias.

Hauser RA. Hauser RA. Geriatrics. 2006 Sep;61(9):14-20. Geriatrics. 2006. PMID: 16989543 Review.

7

Nonmotor symptoms of Parkinson's disease.

Zesiewicz TA, Sullivan KL, Hauser RA. Zesiewicz TA, et al. Among authors: hauser ra. Expert Rev Neurother. 2006 Dec;6(12):1811-22. doi: 10.1586/14737175.6.12.1811. Expert Rev Neurother. 2006. PMID: 17181428 Free article. Review.

8

Advances in the pharmacologic management of early Parkinson disease.

Hauser RA, Zesiewicz TA. Hauser RA, et al. Neurologist. 2007 May;13(3):126-32. doi: 10.1097/01.nrl.0000256433.15481.eb. Neurologist. 2007. PMID: 17495756 Review.

9

Levodopa-induced dyskinesia in Parkinson's disease: epidemiology, etiology, and treatment.

Zesiewicz TA, Sullivan KL, Hauser RA. Zesiewicz TA, et al. Among authors: hauser ra. Curr Neurol Neurosci Rep. 2007 Jul;7(4):302-10. doi: 10.1007/s11910-007-0046-y. Curr Neurol Neurosci Rep. 2007. PMID: 17618536 Review.

10

Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa.

Hauser RA, Rascol O, Korczyn AD, Jon Stoessl A, Watts RL, Poewe W, De Deyn PP, Lang AE. Hauser RA, et al. Mov Disord. 2007 Dec;22(16):2409-17. doi: 10.1002/mds.21743. Mov Disord. 2007. PMID: 17894339 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

332 results

Search Page